Please login to the form below

Not currently logged in
Email:
Password:

FDA conforms to Plan B ruling

The FDA has announced it will not appeal against a federal court's ruling to allow the morning-after pill, Plan B, to be marketed in the US to girls aged 17 and over

The US Food and Drug Administration (FDA) has announced it will not appeal against a federal court's ruling to allow the morning-after pill, Plan B, to be marketed in the US to girls aged 17 and over.

In March 2009, Judge Edward Korman ruled that the FDA decision had been made on political grounds and was not consistent with the scientific findings made in 2005 by the Centre for Drug Evaluation and Research. 

The FDA has since notified Duramed Research, the manufacturers of the emergency contraceptive, that upon submission and approval of an appropriate application, Plan B can be marketed for use by girls over 17 years old without a prescription.

Duramed Research is a subsidiary of Teva Pharmaceuticals.

23rd April 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Porterhouse Medical Group

The Porterhouse Medical Group provides market research, insights, and scientific and medical communication services to the pharmaceutical industry across the...

Latest intelligence

50 questions for delivering an exceptional healthcare brand experience
Our 50-question brand planning checklist for healthcare ensures you deliver an exceptional experience, based on what your stakeholders want and need...
The brand strategy revolution
Introducing a new tool for developing a stakeholder-centric brand, based on the experience your patients and their HCPs want and need....
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....

Infographics